If you have been reading about melanogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-07. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
In series 4, Henry enters politics as a Conservative MP but loses his seat to Jennifer Bevan in a Labour landslide, after which he falls into severe depression that strains his marriage to Yasmin. On his 40th birthday—mirroring the age at which his father committed suicide—he nearly takes his own life but stops himself and accepts an offer from Whitney Halberstram to become CEO of fintech startup Tender. His early tenure includes overseeing Tender’s merger with Austrian bank IBN Bauer and the launch of its banking app. While in Austria, Yasmin arranges a threesome involving Henry and assistant Hayley Clay, which Hayley later reveals was secretly recorded. Henry grows closer to Whitney, who develops a sexual fixation on him and takes him on a bender at a gay club, threatening his sobriety. After Harper exposes Tender’s fraudulent practices, the company’s stock drops 28%. Henry fires the firm’s auditor and confronts Whitney, who gives him a handwritten letter confirming his criminal exposure. Rather than go to authorities, Henry supports Whitney’s attempted takeover of Pierpoint to delay scrutiny, unaware that Yasmin is working with Norton to shift public blame onto Henry and the Labour government. He later learns the takeover was a sham and that he never held a stake in Pierpoint. After Yasmin tells him she no longer loves him and asks for a divorce, Whitney urges Henry to flee to Lithuania, revealing Russian state intelligence is involved in Tender.
Meso-zeaxanthin is produced at an industrial level from the lutein obtained from marigold petals. The process involves saponification, which is carried out using high temperature and a high concentration of base, leads to the isomerization of the 4′-5′ double bond to the 5′-6′ position. This converts the ɛ-ring of lutein into a β-ring, thus converting lutein into meso-zeaxanthin. The stereochemistry of this zeaxanthin is determined by the position of the hydroxyl group at the 3´ position, which results in the "S" designation for the final zeaxanthin molecule. The stereoisomer produced by this process is 3R,3′S-zeaxanthin (i.e., meso-zeaxanthin). The conditions of saponification can be modulated to increase or decrease the conversion rate of lutein into meso-zeaxanthin.
==== 2021: Torn Achilles tendon ==== McCormick did not participate in spring football during his recovery in 2021, though he was cleared to return to practice in July of that year. He participated in the 2021 Oregon Ducks football season opener against the Fresno State Bulldogs, seeing action on special teams. He also played and was named the starter during the Ducks' game against the Ohio State Buckeyes, though he exited the game during the second quarter after suffering a torn Achilles tendon in his right foot, a season-ending injury.
About 89 percent of the bank's $172 billion in deposit liabilities exceeded the maximum insured by the FDIC. Two days after the failure, the FDIC received exceptional authority from the Treasury and announced jointly with other agencies that all depositors would have full access to their funds the next morning. Seeking to auction off all or parts of the bank, the FDIC reopened it on Monday March 13 as a newly organized bridge bank, Silicon Valley Bridge Bank, N.A. Although some characterized the government response as a bailout, the plan did not entail rescuing the bank, its management or shareholders, but rather making uninsured depositors whole from the proceeds of selling the bank's assets, without the use of taxpayer money. The collapse of SVB had significant consequences for startup companies in the U.S. and abroad, with many briefly unable to withdraw money from the bank. Other large technology companies, media companies, and wineries were also affected. For a number of founders and their venture capital backers, this was the bank of choice.
The heart is composed of two atria and two ventricles. The primary purpose of the atria is to allow uninterrupted venous blood flow to the heart during ventricular systole. This allows enough blood to get into the ventricles during atrial systole. Consequently, the atria allow a cardiac output roughly 75% greater than would be possible without them. The purpose of the ventricles is to pump blood to the lungs through the right ventricle and to the rest of the body through the left ventricle. The heart has an electrical conduction system to control the contraction and relaxation of the muscles. It starts in the sinoatrial node traveling through the atria causing them to pump blood into the ventricles. It then travels to the atrioventricular node, which makes the signal slow down slightly allowing the ventricles to fill with blood before pumping it out and starting the cycle over again. Coronary artery disease is the leading cause of death worldwide, making up 16% of all deaths. It is caused by the buildup of plaque in the coronary arteries supplying the heart, eventually the arteries may become so narrow that not enough blood is able to reach the myocardium, a condition known as myocardial infarction or heart attack, this can cause heart failure or cardiac arrest and eventually death. Risk factors for coronary artery disease include obesity, smoking, high cholesterol, high blood pressure, lack of exercise and diabetes. Cancer can affect the heart, though it is exceedingly rare and has usually metastasized from another part of the body such as the lungs or breasts.
Sources: en.wikipedia.org
Diseases that only affect the surface of the cornea can be treated with an operation called phototherapeutic keratectomy (PTK). With the precision of an excimer laser and a modulating agent coating the eye, irregularities on the surface can be removed. However, in most of the cases where corneal transplantation is recommended, PTK would not be effective.
F-ATPase gene linkage and gene order are widely conserved across ancient prokaryote lineages, implying that this system already existed at a date before the last universal common ancestor, the LUCA. Nick Lane: The Vital Question: Energy, Evolution, and the Origins of Complex Life, Ww Norton, 2015-07-20, ISBN 978-0393088816 (Link points to Figure 10 showing model of ATP synthase) Boris A. Feniouk: "ATP synthase — a splendid molecular machine" Well illustrated ATP synthase lecture Archived 2008-12-02 at the Wayback Machine by Antony Crofts of the University of Illinois at Urbana–Champaign. Proton and Sodium translocating F-type, V-type and A-type ATPases in OPM database The Nobel Prize in Chemistry 1997 to Paul D. Boyer and John E. Walker for the enzymatic mechanism of synthesis of ATP; and to Jens C. Skou, for discovery of an ion-transporting enzyme, Na+, K+-ATPase. Harvard Multimedia Production Site — Videos – ATP synthesis animation David Goodsell: "ATP Synthase- Molecule of the Month" Archived 2015-09-05 at the Wayback Machine
Five recognized "nuclear-weapon states" under the terms of the Nuclear Non-Proliferation Treaty (NPT): the United States (first nuclear weapon tested and two bombs used as weapons in 1945), Russia (first weapon tested in 1949), the United Kingdom (1952), France (1960), and China (1964) Three other declared nuclear states that are not signatories of the NPT: India (not a signatory, weapon tested in 1974), Pakistan (not a signatory, weapon tested in 1998), and North Korea (withdrew from the NPT in 2003, weapon tested in 2006) Israel, which is widely known to have developed nuclear weapons (likely first tested in the 1960s or 1970s) but has not openly declared its capability South Africa, which also had enrichment capabilities and developed nuclear weapons (possibly tested in 1979), but disassembled its arsenal and joined the NPT in 1991
== Mechanism of action == Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood. Blocking SGLT-2 reduces blood glucose by blocking glucose reabsorption in the kidney and thereby excreting glucose (i.e., blood sugar) via the urine. Of all the SGLT-2 Inhibitors currently available, empagliflozin has the highest degree of selectivity for SGLT-2 over SGLT-1, SGLT-4, SGLT-5 and SGLT-6.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.